Temasek's full exit is a strong negative signal reflecting loss of institutional confidence. The 45-day 13F lag means these positions may already be unwound; monitor for further selling or negative catalysts. The small buying side lacks the conviction to offset the sovereign exit.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $1.40entry
- T+1 · 5mo ago −2.86%α −4.62% · $1.36
- T+5 · 5mo ago +5.71%α +5.04% · $1.48
- T+20 · 4mo ago +10.00%α +8.22% · $1.54
- T+60 · 2mo ago −2.14%α −5.41% · $1.37
How similar events traded
Executive Summary
In Q3 2024, a small group of asset managers increased CHRS holdings by $795K, while Temasek Holdings fully exited a $10.1M position. The net institutional flow is negative at $9.3M, with Temasek's exit overwhelming accumulation. Historical analysis shows this ticker has underperformed after institutional cluster filings, suggesting caution.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$9.3M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Los Angeles Capital Management | DOUBLED | +344.1% | $967.0K | $605.0K |
| STRS Ohio | DOUBLED | +263% | $357.0K | $193.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Temasek Holdings (Private) | EXIT | -100% | $10.1M | -$10.1M |
| Nisa Investment Advisors | NEAR_EXIT | -80.6% | $36.0K | -$31.6K |
| Pnc Financial Services Group | TRIM | -64.2% | $474.00 | -$372.00 |
Key Facts
- 7 institutional buyers accumulated $1.4M in CHRS (net +$795K) while 3 sellers reduced by $10.1M (net -$9.3M).
- Temasek Holdings exited a $10.1M position (5.82M shares), the dominant seller.
- Los Angeles Capital Management doubled its stake to 930K shares ($967K value).
- STRS Ohio doubled to 343K shares ($357K value).
- Nisa Investment Advisors nearly exited (trimmed 80.6% to 4K shares).
Financial Impact
Net institutional selling of $9.3M in Q3 2024, driven by Temasek's full exit of $10.1M offset by $1.4M in accumulation from 7 asset managers.
Risk Factors
- Continued institutional selling pressure given Temasek's complete exit.
- Low liquidity and high volatility typical of micro-cap biotech.
- Negative clinical or regulatory news that may have prompted the exit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CHRS-2024-Q3 |
Track record
15 reports on CHRS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Viewing Entry $1.40 to $1.37 ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers